Selected article for: "infection time evolution and time evolution"

Author: Lumley, Sheila F; Eyre, David W; McNaughton, Anna L; Howarth, Alison; Hoosdally, Sarah; Hatch, Stephanie B; Kavanagh, James; Chau, Kevin K; Downs, Louise O; Cox, Stuart; Dunn, Laura; Justice, Anita; Wareing, Susan; Dingle, Kate; Rudkin, Justine; Auckland, Kathryn; Fyfe, Alexander; Bolton, Jai; Paton, Robert; Mentzer, Alexander J; Jeffery, Katie; Andersson, Monique I; James, Tim; Peto, Tim E A; Marsden, Brian D; Screaton, Gavin; Cornall, Richard J; Klenerman, Paul; Ebner, Daniel; Stuart, David I; Crook, Derrick W; Stoesser, Nicole; Kennedy, Stephen H; Thompson, Craig; Gupta, Sunetra; Matthews, Philippa C
Title: SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020
  • Cord-id: iwu5bpp5
  • Document date: 2020_10_22
  • ID: iwu5bpp5
    Snippet: SARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among the 53 positive samples, 39 showed in vitro neutralisation activity, correlating with IgG titre (Pearson’s correlation p<0.0001). While SARS-CoV-2 seroprevalence in pregnancy cohorts could potentially inform population surveillance, clinical correlates of infection and immunity in pregnancy
    Document: SARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among the 53 positive samples, 39 showed in vitro neutralisation activity, correlating with IgG titre (Pearson’s correlation p<0.0001). While SARS-CoV-2 seroprevalence in pregnancy cohorts could potentially inform population surveillance, clinical correlates of infection and immunity in pregnancy, and antenatal epidemiology evolution over time need further study.

    Search related documents: